{"id":"hib-2-5","_chembl":null,"modality":"Biologic","_dailymed":null,"mechanism":{"target":"Haemophilus influenzae type b capsular polysaccharide","explanation":"The vaccine works by presenting Hib capsular polysaccharide antigens to the immune system, typically conjugated to a carrier protein to enhance immunogenicity. This triggers the production of antibodies that recognize and neutralize Haemophilus influenzae type b bacteria, providing protective immunity against invasive Hib disease.","oneSentence":"Hib 2.5 is a conjugate vaccine that stimulates immune response against Haemophilus influenzae type b capsular polysaccharide."},"_scrapedAt":"2026-03-28T03:34:11.230Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_claudeStub":{"ts":1779123905,"model":"claude-sonnet-4-5-20250929"},"competitors":[{"name":"Haemophilus b conjugate vaccine","brand":"ActHIB","company":"Sanofi Pasteur","rationale":"Approved Hib conjugate vaccine for prevention of invasive Hib disease"},{"name":"Haemophilus b conjugate vaccine","brand":"Hiberix","company":"GlaxoSmithKline","rationale":"GSK's approved Hib vaccine for active immunization against invasive disease"},{"name":"Haemophilus b conjugate vaccine","brand":"PedvaxHIB","company":"Merck","rationale":"Licensed Hib vaccine providing protection against Haemophilus influenzae type b"}],"description":"Hib 2.5 is an investigational vaccine candidate developed by GlaxoSmithKline currently in Phase 2 clinical trials. It is designed to provide protection against Haemophilus influenzae type b (Hib), a bacterial pathogen that can cause serious invasive diseases including meningitis, pneumonia, and septicemia, particularly in young children.","indications":{"approved":[{"status":"investigational","condition":"Haemophilus influenzae type b infection prevention","patientPopulation":"Paediatric"}]},"trialDetails":[{"nctId":"NCT02097472","phase":"PHASE1, PHASE2","title":"Dose-Finding Study of S.Pneumoniae Whole Cell Vaccine Adsorbed to Alum (PATH-wSP) in Healthy Kenyan Adults and Toddlers","status":"COMPLETED","sponsor":"PATH","startDate":"2014-04","conditions":"Pneumonia, Pneumococcal","enrollment":304},{"nctId":"NCT01061541","phase":"PHASE2","title":"Immunogenicity, Safety & Reactogenicity of GSK Vaccine Tritanrix™-HepB/Hib2.5 Compared to GSK Vaccine Tritanrix™-HepB/Hiberix™","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2003-08","conditions":"Haemophilus Influenzae Type b","enrollment":192}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":87,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Hib 2.5","genericName":"Hib 2.5","companyName":"GlaxoSmithKline","companyId":"gsk","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}